ArticleCancers2024

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

David E Kaplan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.